🟢 Connect Biopharma Holdings Ltd is trading 5.8% up today after Phase 2 asthma trial enrollment milestone

Connect Biopharma Holdings Ltd is trading 5.8% up at $2.20 in after-hours trading after announcing the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study.

• The trial evaluates rademikibart, a next-generation anti-IL-4Rα antibody, a milestone that investors view as de-risking clinical timelines and development execution.
• The stock's after-hours momentum follows a positive regular session where the price gained 4.5%.
• The Seabreeze STAT study is a key component of the company's clinical pipeline for respiratory treatments.